Zeidner, J. F., Foster, M. C., Blackford, A. L., Litzow, M. R., Morris, L. E., Strickland, S. A., Lancet, J. E., Bose, P., Levy, M. Y., Tibes, R., Gojo, I., Gocke, C. D., Rosner, G. L., Little, R. F., Wright, J. J., Doyle, L. A., Smith, B. D., & Karp, J. E. (2018). final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML). Leukemia research, 72, 92–95. http://access.bl.uk/ark:/81055/vdc_100066723783.0x000054